Pacira Pharmaceuticals, Inc. Forecast, price target & analysts
Pacira Pharmaceuticals, Inc. Target price 2025 - Analyst rating & recommendation
Pacira Pharmaceuticals, Inc. Classifications & Recommendation:
Pacira Pharmaceuticals, Inc. Price Target
| Target Price | $32.00 |
| Price | $24.89 |
| Potential |
28.57%
register free of charge
|
| Number of Estimates | 6 |
|
6 Analysts have issued a price target Pacira Pharmaceuticals, Inc. 2026 .
The average Pacira Pharmaceuticals, Inc. target price is $32.00.
This is
28.57%
register free of charge
$48.00
92.85%
register free of charge
$21.00
15.63%
register free of charge
|
|
| A rating was issued by 7 analysts: 3 Analysts recommend Pacira Pharmaceuticals, Inc. to buy, 3 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Pacira Pharmaceuticals, Inc. stock has an average upside potential 2026 of
28.57%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 700.97 | 751.59 |
| 3.85% | 7.22% | |
| EBITDA Margin | 25.16% | 27.59% |
| 4.25% | 9.66% | |
| Net Margin | -14.18% | 8.14% |
| 355.59% | 157.39% |
7 Analysts have issued a sales forecast Pacira Pharmaceuticals, Inc. 2025 . The average Pacira Pharmaceuticals, Inc. sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an Pacira Pharmaceuticals, Inc. EBITDA forecast 2025. The average Pacira Pharmaceuticals, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
4 Pacira Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2025. The average Pacira Pharmaceuticals, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -2.15 | 1.32 |
| 365.43% | 161.40% | |
| P/E | 18.82 | |
| EV/Sales | 1.74 |
4 Analysts have issued a Pacira Pharmaceuticals, Inc. forecast for earnings per share. The average Pacira Pharmaceuticals, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Pacira Pharmaceuticals, Inc....
Current Pacira Pharmaceuticals, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Barclays |
Locked
➜
Locked
|
Locked | Feb 28 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Feb 28 2025 |
| Needham |
Locked
➜
Locked
|
Locked | Feb 28 2025 |
| Truist Securities |
Locked
➜
Locked
|
Locked | Jan 30 2025 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Jan 14 2025 |
| Needham |
Locked
➜
Locked
|
Locked | Jan 13 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Dec 04 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Barclays:
Locked
➜
Locked
|
Feb 28 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Feb 28 2025 |
|
Locked
Needham:
Locked
➜
Locked
|
Feb 28 2025 |
|
Locked
Truist Securities:
Locked
➜
Locked
|
Jan 30 2025 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Jan 14 2025 |
|
Locked
Needham:
Locked
➜
Locked
|
Jan 13 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Dec 04 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
